Royal Bank of Canada Reaffirms “Outperform” Rating for Pyxis Oncology (NASDAQ:PYXS)

Royal Bank of Canada restated their outperform rating on shares of Pyxis Oncology (NASDAQ:PYXS) in a research report sent to investors on Wednesday,Benzinga reports. They currently have a $8.00 price objective on the stock.

Several other research firms also recently commented on PYXS. William Blair downgraded shares of Pyxis Oncology from an “outperform” rating to a “market perform” rating in a research note on Thursday, November 21st. HC Wainwright restated a “buy” rating and set a $5.00 target price on shares of Pyxis Oncology in a research report on Wednesday. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $9.20.

Pyxis Oncology Stock Up 0.9 %

Shares of PYXS stock opened at $1.07 on Wednesday. Pyxis Oncology has a 12-month low of $0.99 and a 12-month high of $6.18. The company has a market capitalization of $63.63 million, a PE ratio of -1.04 and a beta of 1.11. The firm has a 50 day moving average price of $1.34 and a two-hundred day moving average price of $2.39.

Pyxis Oncology (NASDAQ:PYXS) last released its quarterly earnings results on Tuesday, March 18th. The company reported ($0.32) earnings per share for the quarter, topping the consensus estimate of ($0.33) by $0.01. As a group, research analysts expect that Pyxis Oncology will post -1.04 EPS for the current year.

Hedge Funds Weigh In On Pyxis Oncology

Several hedge funds have recently bought and sold shares of the company. Millennium Management LLC lifted its holdings in shares of Pyxis Oncology by 53.8% during the 4th quarter. Millennium Management LLC now owns 2,980,906 shares of the company’s stock worth $4,650,000 after acquiring an additional 1,043,228 shares during the period. Geode Capital Management LLC lifted its stake in Pyxis Oncology by 5.5% during the third quarter. Geode Capital Management LLC now owns 1,084,727 shares of the company’s stock worth $3,982,000 after purchasing an additional 57,016 shares during the last quarter. State Street Corp boosted its holdings in shares of Pyxis Oncology by 28.0% in the 3rd quarter. State Street Corp now owns 951,251 shares of the company’s stock valued at $3,491,000 after purchasing an additional 208,344 shares in the last quarter. Jacobs Levy Equity Management Inc. increased its stake in shares of Pyxis Oncology by 57.2% in the 4th quarter. Jacobs Levy Equity Management Inc. now owns 601,940 shares of the company’s stock valued at $939,000 after purchasing an additional 219,100 shares during the last quarter. Finally, Ridgeback Capital Investments L.P. acquired a new position in shares of Pyxis Oncology during the 4th quarter worth $560,000. 39.09% of the stock is owned by institutional investors.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.